EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Orforglipron in type 2 diabetes mellitus and obesity: an overview

Theodoros Panou, Evanthia Gouveri, Djordje S Popovic, Nikolaos Papanas

Expert Review of Clinical Pharmacology · 2025

DOI: 10.1080/17512433.2025.2594493 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2025. Verfasst von Theodoros Panou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the management of type 2 diabetes mellitus (T2DM) and obesity. AREAS COVERED: An electronic search was conducted in Scopus, PubMed/MEDLINE, and Google Scholar databases. Orforglipron is a novel oral non-peptide GLP-1RA. In T2DM individuals, it has led to reductions in glycated hemoglobin (HbA1c) by up to 2.10%, in weight by up to 10.1 kg and in waist circumference by up to 8.7 cm. In studies on overweight or obesity, a weight loss up to 13.0 kg has been reported. In meta-analyses, orforglipron was the most efficient GLP-1RA in terms of weight loss. Significant decreases in systolic blood pressure have also been found in individuals with and without T2DM. Untoward effects include mild-to-moderate vomiting and nausea, particularly in those receiving high doses and after rapid-dose escalation. EXPERT OPINION: Orforglipron is a promising treatment option for T2DM and overweight or obesity, in terms of glucose control and weight loss. The increased frequency of adverse events, particularly in those receiving high doses and after rapid-dose escalation, requires caution before widespread use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ObesityHypoglycemic AgentsHumansWeight LossGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinDose-Response Relationship, DrugWaist CircumferenceOverweightBlood PressureAnimalsOxadiazolesFluorine Compounds

Stichwörter der Autor:innen

LY3502970Orforglipronglucagon-like peptide-1 receptor agonistsobesitytype 2 diabetes mellitus

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlycated Hemoglobinhemoglobin A1c protein, humanorforglipronOxadiazolesFluorine Compounds

Autor:innen und Institutionen

  • Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
  • Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Novi Sad, Serbia.
  • Medical Faculty, University of Novi Sad, Novi Sad, Serbia.

Zitieren

APA

Panou, T., Gouveri, E., Popovic, D. S., & Papanas, N. (2025). Orforglipron in type 2 diabetes mellitus and obesity: an overview. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2594493

Vancouver

Panou T, Gouveri E, Popovic DS, Papanas N. Orforglipron in type 2 diabetes mellitus and obesity: an overview. Expert Review of Clinical Pharmacology. 2025. doi:10.1080/17512433.2025.2594493

BibTeX
@article{Panou2025,
  author = {Panou, Theodoros and Gouveri, Evanthia and Popovic, Djordje S and Papanas, Nikolaos},
  title = {Orforglipron in type 2 diabetes mellitus and obesity: an overview},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2025},
  doi = {10.1080/17512433.2025.2594493}
}
Kostenlos starten →